adding notes
parent
4bf321b475
commit
1672210931
@ -0,0 +1,25 @@
|
||||
Key points
|
||||
|
||||
This is an attempt at measuring the effect of extending the enrollment period.
|
||||
The main issue is that the interaction between enrollment levels, enrollment status, and timing is confounded due to endogeneity.
|
||||
This can be addressed
|
||||
|
||||
The other concerns are:
|
||||
- endogeneity between market and population.
|
||||
I this isn't a caual issue because it is contained between the two, can be treated as a single RV and controlled for together.
|
||||
- ommitted variable bias. Did I forget or miss anything?
|
||||
- The DAG is based on the details outlined based on FDA rules. I NEED TO LOOK THOSE UP AGAIN. The Assumptions that allow this to work are:
|
||||
1. timeliness/accuracy in reporting open and close
|
||||
2. updating certain details (open/close recruitment) is helpful because this is part of your marketing. (Concerns about measurement error)
|
||||
3.
|
||||
- Where did the DAG come from?
|
||||
|
||||
In spite of the endogeneity issue, I chose to continue modelling as if it were causal, because:
|
||||
1. If we assume an intervetion that is handles the joint timing/enrollment status together, then it is causally identified (but hard to interpret)
|
||||
- Walking away from identification is an issue in that you lose the use of this analysis
|
||||
- Interpretation is as follows: changing enrollment status but breaking out of the standard timing of these things. Need a better way to say that.
|
||||
2.
|
||||
|
||||
|
||||
This is the only attempt I've found that tries to address this in a causal way, everything else is just descriptive.
|
||||
It also differs in being the first econ literature on measuring the impact of an operational concern.
|
||||
Loading…
Reference in New Issue